SCHEMBL20833486

SCHEMBL20833486

CNC1(C)C2CCC(C2)C1(C)O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.60
CHRNB4 P30926 4/20 0.60
CHRNA3 P32297 4/20 0.60
CHRNA7 P36544 4/20 0.60
CHRNA4 P43681 4/20 0.60
CHRNA1 P02708 3/20 0.60
CHRNG P07510 3/20 0.60
CHRNB1 P11230 3/20 0.60
CHRND Q07001 3/20 0.60
LMNA P02545 1/20 0.60
CYP3A4 P08684 1/20 0.60
PKM P14618 1/20 0.60
NFKB1 P19838 1/20 0.60
CYP2C19 P33261 1/20 0.60
THPO P40225 1/20 0.60
CHRNE Q04844 1/20 0.60
CHRNA2 Q15822 1/20 0.60
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2(R)-Mecamylamine SCHEMBL308575 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL3008785 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL34253 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Dexmecamylamine SCHEMBL29376444 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL7208020 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL34252 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL4416036 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL11028235 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL3007951 0.75 CHRNB2 (1.00) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
Mecamylamine SCHEMBL7440931 0.73 CHRNB2 (0.95) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 US disclosed
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 US disclosed
WO-2020191252-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-09-24 WO disclosed
US-20200231620-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-07-23 US disclosed
WO-2019055951-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718638-B2 Compounds, compositions and methods for synthesis ALKBH1, DUT, RNGTT CHRNB2 2464/4885CHRNB4 2143/4885CHRNA3 2264/4885
US-20200231620-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT CHRNB2 1731/4885CHRNB4 1155/4885CHRNA3 2340/4885
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT CHRNB2 1731/4885CHRNB4 1155/4885CHRNA3 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.